欢迎来到《四川大学学报(医学版)》

罗哌卡因伍用右美托咪定前锯肌平面阻滞联合静脉自控镇痛对胸腔镜肺癌根治术患者术后恢复质量的改善作用

Effect of Ropivacaine Combined with Dexmedetomidine for Serratus Anterior Plane Block Plus Patient-Controlled Intravenous Analgesia on Postoperative Recovery Quality of Patients Undergoing Thoracoscopic Radical Resection of Lung Cancer

  • 摘要:
      目的  研究罗哌卡因伍用右美托咪定在超声可视下前锯肌平面阻滞(SAPB)、联合静脉自控镇痛(PCIA)对胸腔镜肺癌根治术后的镇痛效果。
      方法  择期胸腔镜手术患者129例,随机分为3组(n=43):生理盐水组(对照组)、罗哌卡因组(R组)和罗哌卡因联合右美托咪定组(RD组)。3组患侧前锯肌平面阻滞,分别注入0.9%生理盐水0 mL、0.5%罗哌卡因25 mL和0.5%罗哌卡因+1 μg/kg右美托咪定混合液25 mL;同时均使用PCIA。术后患者咳嗽时疼痛视觉模拟评分(VAS)≥4分,则静脉给予舒芬太尼2.5 μg补救。主要观察指标为拔除气管导管后10 min、6 h、12 h、24 h和48 h静息和咳嗽时VAS评分。次要观察指标包括血流动力学、术后前3夜睡眠质量、PCIA按压次数、术中和术后阿片类药物用量、术后首次补救镇痛时间、拔除胸管时间、住院时间、不良反应等。
      结果  与对照组相比,R组和RD组在拔管后10 min、6 h、12 h时VAS评分更低(P<0.05)。与R组比较,RD组需要补救镇痛的患者人数、第一次抢救镇痛时间、PCIA按压次数和补救舒芬太尼总剂量均减少(P<0.05),RD组术后第二、三夜睡眠质量更好,恶心与呕吐发生率更低(P<0.05)。
      结论  0.5%罗哌卡因伍用1 μg/kg右美托咪定SAPB联合PCIA可明显减轻胸腔镜肺癌根治术患者术后疼痛,改善术后恢复质量。

     

    Abstract:
      Objective  To study the postoperative analgesic effect of ropivacaine combined with dexmedetomidine for serratus anterior plane block (SAPB) under ultrasound visualization plus patient-controlled intravenous analgesia (PCIA) in patients undergoing thoracoscopic radical resection of lung cancer.
      Methods  A total of 129 patients undergoing elective thoracoscopic surgery were enrolled. The patients were randomly assigned to three groups (n=43 in each group), a normal saline group (control group), a ropivacaine mesylate group (Group R) and a ropivacaine mesylate combined with dexmetomidine hydrochloride group (Group RD). After operation, ultrasound-guided SAPB was performed and patients in the three groups received the injection of 0 mL of 0.9% normal saline, 25 mL of 0.5% ropivacaine, and 25 mL of 0.5% ropivacaine+1 μg/kg dextrometomidine hydrochloride mixture, respectively. In addition, PCIA was used for all the patients. The button on the PCIA pump was pressed when the postoperative pain visual analogue score (VAS)≥4 on coughing, and rescue analgesic of sufentanil was given intravenously at 2.5 μg/bolus. The primary outcome was the VAS scores at rest and on coughing at 10 min (T1), 6 h (T2), 12 h (T3), 24 h (T4), and 48 h (T5) after extubation. The secondary outcomes included hemodynamics, the quality of sleep for the first 3 nights after operation, number of times the button on the PCIA pump was pressed, intraoperative and postoperative opioid dosage, time of first postoperative rescue analgesic, duraion of intubation, length of stay at the hospital, adverse reactions, etc.
      Results  Compared with those of the control group, the VAS scores of the Group R and Group RD were significantly lower at 10 min, 6 h, and 12 h after extubation (P<0.05). In comparison with Group R, the number of patients requiring rescue analgesia, the time of first postoperative rescue analgesic, the number of times the button on the PCIA pump was pressed, and the total dose of rescue sufentanil were all significantly lower (P<0.05) in the Group RD. Patients in the Group RD had better sleep quality in the second and third nights after operation and lower incidence of nausea and vomiting (P<0.05).
      Conclusion  0.5% ropivacaine and 1 μg/kg dexmedetomidine SAPB combined with PCIA can significantly reduce postoperative pain and improve postoperative recovery quality in patients undergoing thoracoscopic radical resection of lung cancer.

     

/

返回文章
返回